drugset / Trial / NCT06271538

Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome

NCT06271538

Phase 4 Recruiting 60 enrolled EP Plus Group Sdn Bhd
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.

Timeline

Start
2024-10-17
Primary completion
2026-03-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus plantarum 299v Other / unclassified 1e+10 unknown
Subject galactooligosaccharides Unknown